Lung cancer remains a pressing concern in global health. A large percentage of patients are diagnosed early. This cancer, called metastatic when it goes beyond the lungs, is rising globally. America's sixth most prevalent illness is lung cancer. Alarmingly, 20% of cancer deaths there are caused by it. Lung cancer was expected to increase by 14,700 in 2023.
Lung cancer can primarily be classified into two categories:
NSCLC accounts for approximately 85% of all lung cancer diagnoses.
Within the umbrella of NSCLC, there are various subtypes. The most prevalent subtype is:
Recognizing and addressing lung cancer's distinct types and implications is imperative, as early diagnosis and treatment can significantly impact outcomes.
Lung cancer's progression is typically classified into distinct lung cancer stages, which help guide treatment decisions and predict patient outcomes. The phases depend on tumor size, location, and dissemination. Remember that cancer staging might be more complicated than it seems. For instance, a Stage III cancer might have a smaller tumor than a Stage II cancer. Yet, other factors can make Stage III cancer more severe.
Here's a more detailed breakdown of each stage:
At this earliest stage, cancer cells are present only in the top layer of cells lining the air passages and have not invaded deeper tissues.
The cancer hasn't spread beyond the upper layer or reached the surrounding lung tissue or other areas.
If you are facing any of these signs and symptoms of lung cancer, you must see a doctor because this is alarming.
Here are a few reasons that might increase your risk of catching this deadly cancer.
Different tests are used to detect tumors and define their type and stage in lung cancer. The usual processes are examined in detail here:
After lung cancer diagnosis, it's common to worry about treatment options. Cancer kind, stage, genetics, and patient condition often determine treatment.
The cancer stage determines the treatment plan after diagnosis. TNM determines the main tumor's size and metastasis to lymph nodes and other organs. It classifies the tumor's (T) size and extent, surrounding lymph nodes (N), and metastasis (M), which indicates whether the malignancy has spread.
Surgery is often the first treatment for early-stage non-small cell lung cancer. Surgery has three primary types:
Radiotherapy employs X-rays to target and destroy cancer cells as a standalone treatment or in conjunction with surgery or chemotherapy. This approach is often viable for locally advanced (stage III) non-small cell lung cancer and can be a good option if surgery isn't possible. Radiotherapy might also be used post-surgery to treat any areas where cancer cells remain.
Thermal ablation can be a viable option for patients who cannot undergo surgery or radiation, particularly in the case of locally advanced NSCLC in Stage I. This procedure uses needles to deliver heat directly to the tumor, killing cancer cells.
Cancer cells are targeted by chemotherapy, which treats small and non-small cell lung cancers. Before surgery to shrink the tumor, with radiation therapy to boost its efficacy, or after surgery to reduce recurrence.
Immunotherapy leverages the body’s immune system to fight cancer cells and is sometimes used to treat non-small cell lung cancers.
This innovative approach involves personalized medicine, wherein therapies are designed to target cancer cells with specific mutations. It's often utilized for advanced non-small cell lung cancer, tailoring treatments to the individual characteristics of a patient's cancer cells to yield better outcomes potentially.
The term "prognosis" refers to a disease's anticipated course and outcome. No doctor can anticipate the progression of an illness, but they can provide insights based on average outcomes for similar cancer kinds and lung cancer stages. When evaluating a prognosis, your doctor will evaluate your test findings, lung cancer type, tumor growth rate, tumor extent, age, health, and smoking history. Early cancer detection improves treatment.